Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

Vaccines Europe at a glance

Vaccines Europe acts as the cohesive voice of the Europe-based vaccine industry sector and is a trusted partner for public authorities. Find out more about our association and contribution to Europe.

Start Prezi

The vaccine industry
in figures

With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.

Find out more

A new age in immunisation

The vaccine industry is actively engaged in research & development of new vaccines that target diseases difficult to treat such as HIV/AIDS, cancer, Alzheimer and malaria among others, in view of improving public health.

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News


“BE BOLD, BE BRAVE, AND BE CREATIVE” Commissioner Tonio Borg call to develop innovative and sustainable approaches to prevention and disease management at first EU Chronic Disease Summit, 03-04 April 2014

2014 04 16 Written by Vaccines Europe

Vaccines Europe was pleased to be invited to attend and play an active role in occasion of the first EU Summit on Chronic Diseases organised and hosted by the European Commission’s Directorate-General for Health & Consumers last 3-4 April 2014.

The Summit brought together a set of high-level stakeholders representatives of governments, public health authorities, research organisations, insurers, industry, patients, and the NGO community to join voices in discussing the increasingly pressing burden posed by chronic diseases in the EU, which is set to rise with the projected demographic change and growing number of elderly. Read more…

EU-funded FLURESP project provides evidence of cost-effectiveness of vaccination strategies in influenza pandemic scenarios

2014 03 31 Written by Vaccines Europe

Vaccines Europe was pleased to attend the Final Conference of the DG SANCO-funded FLURESP project hosted last 28 March 2014 in Luxembourg, chaired by Dr. Ariel Beresniak from the French University of Paris-Descartes.

 Funded under the 2nd EU Health Programme 2008-2013, FLURESP aimed to assess the performance and socio-economic impact of difference response strategies for human influenza pandemics in Europe in order to improve European preparedness planning and support decision-making in the framework of national pandemic preparedness plans. Effective prioritisation requires relevant information to refrain decision makers from premature commitment of resources as well as a willingness to use tools and processes that lead to informed and responsible decisions. Read more…

Save the date: ESWI 5th Influenza Conference, Riga, 14-17 September 2014

2014 03 28 Written by Vaccines Europe

The European Scientific Working group on Influenza (ESWI) is hosting the fifth edition of its ESWI Influenza Conferences in Riga, Latvia, on 14–17 September 2014. Over the past 11 years, the ESWI Influenza Conferences have grown into the largest European scientific conferences entirely dedicated to influenza. Read more…

See all News